NCT06399172Not yet recruiting
OncoSil Pancreatic Cancer Post-marketing Clinical Registry - Italy
OncoSil Pancreatic Cancer Post-marketing Clinical Registry Italy
Source: ClinicalTrials.gov · Last updated 3 May 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The OSPRItaly Patient Registry has been developed to assess the performance and safety of the OncoSil™ device when used within the approved indication of unresectable, locally advanced pancreatic cancer, in combination with gemcitabine-based chemotherapy, within a real-world observational registry.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 23 Apr 2024
- Start date
- 30 May 2024
- Primary completion date
- 30 May 2029
- Lead sponsor
- OncoSil Medical Limited
- Diseases
- Pancreatic cancer
- NCT number
- NCT06399172
What you commit to
- Study type: Observational
- Planned participants: 50
- From 30 May 2024 to the primary completion date, 30 May 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of an investigational agent at the time of enrolment.
Other
- Patients participating in an interventional clinical study (company or investigator-sponsored).
Who the study is looking for
- Patients who are eligible for and undergo OncoSil™ implantation at an eligible treatment facility according to the approved OncoSil™ System Instructions for Use (IFU), as part of their clinical care.
- Patients who have completed and signed the Patient Informed Consent Form (PICF) for the OSPRItaly Patient Registry.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.